A Foundational Study On Stroke Is Ready. Here Is Why It’s Important
Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for huma
Battling With Booze? Here’s A Deeper Look At Ketamine for Alcohol Use Disorder
This article by Elisabetta Fato was originally published on Microdose and appears here with permission.
In the last decades, there has been a growing interest in psychedelics for the treatment of mood and behavioral disorders, among which are substance use disorders.
Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has set up a clinical research program for the treatment of strokes, focused on its proprietary DMT analogue, AP-188. The company is also planning to begin a Phase 1 clinical trial in 2022’s fourth quarter.
Using LSD To Treat Anxiety Is Showing Some Encouraging Findings In A Clinical Trial
A new scientific publication recently came out in the Biological Psychiatry journal announcing that results of an ongoing
Canadian Psychedelics Company Reduces Manufacturing Time Of MDMA By Two Thirds
Nirvana Life Sciences Inc. (CSE: NIRV) announced that it has engineered a method that reduces the manufacturing time of MDMA by two thirds.
Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries
Psychedelics R&D company Mindset Pharma (OTCQB: MSSTF) has filed no less than 16 national applications, including countries within the main South East Asian markets, for one of its key families of next-generation psychedelic compounds.
Psychedelic Mushrooms Are Going Global: Supply Deal With UK-Based Wellness Company Moves Forward
Expert functional and magic mushrooms grower Optimi Health Corp. (OTCQX: OPTHF) has signed an agreement with Avida Global, a privately-held UK-based producer of white label products including nutraceuticals and medicinal cannabis oils.
Intradermal Ketamine Patch Completes Pre-Clinical Phase, Advances To Clinical Studies
PharmaTher Holdings (OTCQB: PHRRF), the biopharma company developing novel uses and delivery forms of ketamine for mental health treatments, has completed an IND-enabling pharmacokinetic and tolerability study of its ketamine patch, KETARX, in minipigs.
Most, But Not All, Psychedelics Companies Have Sufficient Liquidity
The Chart represents the liquidity positions of the 21 Psychedelic sector companies in the Viridian Value Tracker database.
Wesana Sells Clinic Management Services Organization To Strengthen Assets
Life sciences company Wesana Health (OTCQB: WSNAF) has completed the sale of its indirect, wholly-owned subsidiary Advanced Psychiatric Management LLC for a total of $2,100,000.